Finance

Lists
Outlook: 68.2% bullish·0.0% bearish
Go to analysis
ABT:NYSE
Abbott Laboratories
98,49 $
-0,24%
(-0,24) 1D
98,50 $
+0,01% (+0,010)
After hours
Closed: 8 қаз., 16:02:38 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABT...
Open
98,56 $
High
99,20 $
Low
97,20 $
Mkt. cap
170,43 млрд
Avg. vol.
8,77 млн
Volume
0,00
Dividend
2,56%
Quarterly dividend
0,63 $
Ex-dividend date
2026 ж. 15 қаз.
P/E ratio
31,70
52-wk high
135,12 $
52-wk low
81,97 $
EPS
3,11 $
Beta
0,59
Shares outstanding
1,73 млрд
No. of employees
115 м.
Open
98,56 $
High
99,20 $
Low
97,20 $
Mkt. cap
170,43 млрд
Avg. vol.
8,77 млн
Volume
0,00
Dividend
2,56%
Quarterly dividend
0,63 $
Ex-dividend date
2026 ж. 15 қаз.
P/E ratio
31,70
52-wk high
135,12 $
52-wk low
81,97 $
EPS
3,11 $
Beta
0,59
Shares outstanding
1,73 млрд
No. of employees
115 м.
News stories
From web sources and news partners
Profile
Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company founded in Chicago with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States, diagnostic products, nutritional products, and medical devices. Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT and MitraClip. The company is ranked 107th on the Fortune 500 and 144th on the Forbes Global 2000. Wikipedia
About Abbott Laboratories
CEORobert B. Ford
Employees115 м.
Founded1888
HeadquartersЧикаго, Иллинойс, Америка Құрама Штаттары
SectorMedical device
Websiteabbott.com
Analyst ratings
Based on 14 analysts giving stock ratings to ABT in the past 3 months
Strong buy
Buy
14
Hold
0
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for ABT in the last 3 months.
Highest
Current 98,49 $
135,00 $ (+37,07%)
Average
125,50 $ (+27,42%)
Lowest
112,00 $ (+13,72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matt Miksic
Barclays
Buy
Maintained
120,00 $
+21,8%
10/07/2026
Himanshu Patel
J.P. Morgan
Buy
Initiated
120,00 $
+21,8%
10/07/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
112,00 $
+13,7%
10/05/2026
Joanne Wuensch
Citi
Buy
Maintained
125,00 $
+26,9%
10/05/2026
Travis Steed
Bank of America Securities
Buy
Maintained
115,00 $
+16,8%
10/01/2026
Ed Ridley-Day
Rothschild & Co Redburn
Buy
Upgraded
127,00 $
+28,9%
10/02/2026
Kendall Au
RBC Capital
Buy
Maintained
130,00 $
+32%
10/01/2026
Josh Jennings
TD Cowen
Buy
Reiterated
135,00 $
+37,1%
09/14/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
-
-
09/01/2026
Adam Maeder
Piper Sandler
Buy
Maintained
118,00 $
+19,8%
08/26/2026
Matthew Taylor
Jefferies
Buy
Reiterated
135,00 $
+37,1%
08/21/2026
Marie Thibault
BTIG
Buy
Maintained
134,00 $
+36,1%
08/20/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
08/21/2026
Michael Polark
Wolfe Research
Buy
Upgraded
130,00 $
+32%
08/13/2026
Danielle Antalffy
UBS
Buy
Reiterated
125,00 $
+26,9%
07/28/2026
Patrick Wood
UBS
Buy
Reiterated
125,00 $
+26,9%
07/28/2026
Unknown Analyst
Jefferies
Buy
Reiterated
135,00 $
+37,1%
07/17/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
130,00 $
+32%
07/16/2026
Jayson Bedford
Raymond James
Buy
Maintained
-
-
07/17/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
112,00 $
+13,7%
07/06/2026
David Rescott
Robert W. Baird
Buy
Initiated
121,00 $
+22,9%
06/30/2026
Unknown Analyst
J.P. Morgan
Buy
Maintained
110,00 $
+11,7%
06/29/2026
David Roman
Goldman Sachs
Buy
Maintained
113,00 $
+14,7%
05/31/2026
Narumi Nakagiri
Daiwa
Hold
Downgraded
92,00 $
-6,6%
04/21/2026
Anthony Petrone
Mizuho Securities
Hold
Maintained
115,00 $
+16,8%
04/20/2026
Suraj Kalia
Oppenheimer
Buy
Maintained
115,00 $
+16,8%
04/17/2026
Bruce Jackson
Benchmark Co.
Buy
Maintained
120,00 $
+21,8%
04/17/2026
Rick Wise
Stifel Nicolaus
Buy
Reiterated
120,00 $
+21,8%
04/17/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
121,00 $
+22,9%
04/09/2026
Unknown Analyst
Erste Group
Hold
Maintained
-
-
04/01/2026
Next call 12 күннен кейін
21 қаз., ср, 15:00
Fiscal period
Q3 2026
EPS / Est. (USD)
- / 1,42 $
Revenue / Est. (USD)
- / 12,99 млрд
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
11,37 млрд
11,46 млрд
11,16 млрд
12,59 млрд
Cost of goods sold
5,08 млрд
4,91 млрд
4,89 млрд
5,32 млрд
Cost of revenue
5,08 млрд
4,91 млрд
4,89 млрд
5,32 млрд
Research and development expenses
766,00 млн
720,00 млн
767,00 млн
892,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,90 млрд
2,93 млрд
3,58 млрд
3,87 млрд
Operating expense
4,09 млрд
4,07 млрд
4,77 млрд
5,42 млрд
Total operating expenses
9,16 млрд
8,98 млрд
9,66 млрд
10,74 млрд
Operating income
2,20 млрд
2,48 млрд
1,50 млрд
1,85 млрд
Other non operating income
2,00 млн
-15,00 млн
-
-25,00 млн
EBT including unusual items
2,18 млрд
2,36 млрд
1,45 млрд
1,52 млрд
EBT excluding unusual items
2,18 млрд
2,44 млрд
1,45 млрд
1,52 млрд
Income tax expense
536,00 млн
582,00 млн
372,00 млн
596,00 млн
Effective tax rate
24,59%
24,68%
25,67%
39,11%
Other operating expenses
-
-
-
-
Net income
1,64 млрд
1,78 млрд
1,08 млрд
928,00 млн
Net profit margin
14,46%
15,50%
9,65%
7,37%
Earnings per share
1,30
1,50
1,15
1,31
Interest and investment income
77,00 млн
78,00 млн
106,00 млн
52,00 млн
Interest expense
-121,00 млн
-120,00 млн
-174,00 млн
-351,00 млн
Net interest expenses
-44,00 млн
-42,00 млн
-68,00 млн
-299,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
3,00 млрд
3,27 млрд
2,31 млрд
2,91 млрд
Gain or loss from assets sale
-
65,00 млн
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары